Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company ...

The global cancer supportive care products market is set to experience steady growth, with an estimated market value of USD 20.63 billion in 2022. According to industry forecasts, this market is ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

Biocon’s share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company’s seventh USFDA ...

The Reuters poll of City economists had predicted growth of just 0.1 per cent. Even with the usual caveats – that this is just the first estimate, monthly figures are volatile, and the ONS hasn ...

Jobevne is a recombinant humanised monoclonal antibody which functions as a vascular endothelial growth factor inhibitor ... which includes Fulphila (Pegfilgrastim-jmdb) and Ogivri (Trastuzumab-dkst).

Donald Trump’s trade war will have a ‘chilling effect’ on UK growth, a leading Bank of England official has warned. As market carnage showed little sign of abating yesterday, Sarah Breeden ...

Biocon Biologics Ltd today announced that the U.S. FDA has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used ...

JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and ... which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets ...

Finance Minister Nicola Willis warned on April 8 that the Treasury now expected growth from its trading partners to be at 2 per cent in 2026, down from earlier forecasts of 2.5 per cent.